870962-68-8Relevant articles and documents
Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
Wissner, Allan,Fraser, Heidi L.,Ingalls, Charles L.,Dushin, Russell G.,Floyd, M. Brawner,Cheung, Kinwang,Nittoli, Thomas,Ravi, Malini R.,Tan, Xingzhi,Loganzo, Frank
, p. 3635 - 3648 (2008/02/07)
A series of 4-dimethylamino-but-2-enoic acid [4-(3,6-dioxo-cyclohexa-1,4-dienylamino)-7-ethoxy-quinazolin-6-yl]-amide derivatives were prepared. These compounds have two independent reactive centers and were designed to function as dual irreversible inhib